Please try another search
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company’s lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Patrick Fabbio | 56 | 2018 | Independent Director |
Yan Sun | - | - | Member of Scientific Advisors & Principal Investigators Board |
Douglas W. Blayney | 74 | - | Member of Scientific Advisors & Principal Investigators Board |
Yuankai Shi | - | - | Member of Scientific Advisors & Principal Investigators Board |
Matthew Kirkby | 55 | 2016 | Independent Director |
David S. Ettinger | - | - | Member of Scientific Advisors & Principal Investigators Board |
Jeffrey Crawford | - | - | Member of Scientific Advisors & Principal Investigators Board |
Lan Huang | 53 | 2014 | Co-Founder, Chairman & CEO |
Jiangwen Majeti | 56 | 2022 | Independent Director |
Brendan P. Delaney | 49 | 2021 | Independent Director |
Sihai Xu | 52 | 2022 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review